Stikbakke Einar, Wilsgaard Tom, Haugnes Hege Sagstuen, Pedersen Mona Irene, Knutsen Tore, Støyten Martin, Giovannucci Edward, Eggen Anne Elise, Thune Inger, Richardsen Elin
Department of Clinical Medicine, Faculty of Health Sciences, UiT, The Arctic University of Norway, 9037 Tromsø, Norway.
Department of Oncology, University Hospital of North Norway, 9038 Tromsø, Norway.
Cancers (Basel). 2022 Feb 23;14(5):1142. doi: 10.3390/cancers14051142.
The role of miR-24-1-5p and its prognostic implications associated with prostate cancer are mainly unknown. In a population-based cohort, the Prostate Cancer Study throughout life (PROCA-life), all men had a general health examination at study entry and were followed between 1994 and 2016. Patients with available tissue samples after a prostatectomy with curative intent were identified (n = 189). The tissue expression of miR-24-1-5p in prostate cancer was examined by in situ hybridization (ISH) in tissue microarray (TMA) blocks by semi-quantitative scoring by two independent investigators. Multivariable Cox regression models were used to study the associations between miR-24-1-5p expression and prostate cancer recurrence. The prostate cancer patients had a median age of 65.0 years (range 47−75 years). The Cancer of the Prostate Risk Assessment Postsurgical Score, International Society of Urological Pathology grade group, and European Association of Urology Risk group were all significant prognostic factors for five-year recurrence-free survival (p < 0.001). Prostate cancer patients with a high miR-24-1-5p expression (≥1.57) in the tissue had a doubled risk of recurrence compared to patients with low expression (HR 1.99, 95% CI 1.13−3.51). Our study suggests that a high expression of miR-24-1-5p is associated with an increased risk of recurrence of prostate cancer after radical prostatectomy, which points to the potential diagnostic and therapeutic value of detecting miR-24-1-5p in prostate cancer cases.
miR-24-1-5p的作用及其与前列腺癌相关的预后意义主要尚不清楚。在一项基于人群的队列研究“终生前列腺癌研究(PROCA-life)”中,所有男性在研究开始时均进行了全面健康检查,并在1994年至2016年期间接受随访。确定了具有根治性前列腺切除术后可用组织样本的患者(n = 189)。通过组织微阵列(TMA)块中的原位杂交(ISH),由两名独立研究人员进行半定量评分,检测前列腺癌中miR-24-1-5p的组织表达。使用多变量Cox回归模型研究miR-24-1-5p表达与前列腺癌复发之间的关联。前列腺癌患者的中位年龄为65.0岁(范围47-75岁)。前列腺癌风险评估术后评分、国际泌尿病理学会分级组和欧洲泌尿外科协会风险组均是五年无复发生存率的重要预后因素(p < 0.001)。组织中miR-24-1-5p高表达(≥1.57)的前列腺癌患者与低表达患者相比,复发风险增加一倍(HR 1.99, 95% CI 1.13-3.51)。我们的研究表明miR-24-1-5p高表达与根治性前列腺切除术后前列腺癌复发风险增加相关,这表明在前列腺癌病例中检测miR-24-1-5p具有潜在诊断和治疗价值。